Inovio Pharma (INO) reported Q4 EPS of ($1.17), $1.00 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $10.26 million versus the consensus estimate of $339.28 thousand.
Inovio Pharma (INO) reported Q4 EPS of ($1.17), $1.00 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $10.26 million versus the consensus estimate of $339.28 thousand.